What are the differences and characteristics between cabergoline and bromocriptine

Among the drugs for the treatment of hyperprolactinemia (HPRL) and prolactinoma cabergoline and bromocriptine (Bromocriptine) are the two most widely used dopamine receptor agonists in clinical practice. Although the two have similar mechanisms of action, both inhibiting pituitary prolactin secretion by stimulating D2 receptors, they are different in terms of pharmacological properties, persistence of efficacy and tolerance.

First of all, cabergoline has the characteristics of long half-life and low dosing frequency in terms of pharmacokinetics. Most patients can usually maintain a stable therapeutic effect by taking it once or twice a week. However, bromocriptine often needs to be taken multiple times a day due to its short action time. This difference not only brings convenience to patients in terms of compliance, but also shows obvious advantages in long-term treatment.

Secondly, in terms of efficacy, many international guidelines have pointed out that cabergoline is more effective in reducing serum prolactin levels and reducing the size of prolactinoma, and its response rate is often better than bromocriptine. Cabergoline is often the first choice alternative for patients who have poor tolerance or poor response to bromocriptine.

Tolerance is also one of the differences between the two. Common adverse reactions of bromocriptine include nausea, dizziness, gastrointestinal discomfort, etc. Some patients interrupt treatment due to obvious symptoms. The incidence of adverse reactions of cabergoline is relatively low, mostly manifesting as mild headache or transient hypotension, and has little impact on daily life. Therefore, in clinical practice, doctors prefer cabergoline as the first choice for long-term medication.

Finally, bromocriptine is generally more economical in terms of cost and accessibility, but as generic cabergoline becomes more common, barriers to use are lowering.

Overall, cabergoline has gradually become the main drug for the treatment of prolactin-related diseases due to its accurate efficacy, convenient administration, and good tolerability, while bromocriptine is more used in individual cost-sensitive or cabergoline-intolerant patients.

Reference materials:https://www.drugs.com/mtm/cabergoline.html